Nice | Empagliflozin in Type 2 Diabetes

5th June 2015 by Louise Hudman

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my post about Dapagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

Read for free

Sign up to access everything.

Free trial

Login

Already a member? Login to view this content.

Login

"I am so glad and grateful for being a member of NASGP's BOB locum chambers. I started with them in a critical period of my career as I was a newly-qualified GP, looking for work in a new area with a new virus hardly hitting the world and the jobs market.

Richard and Ali's help was a godsend. They introduced me to locum work in a friendly and kind manner, provided valuable support and excellent service through the ever-improving LocumDeck and NASGP website. With the help of the chambers, I received a face to face tutorial on Emis (I trained on SystmOne) and my online profile was promoted on a growing network of GP practices throughout Buckinghamshire, Oxford and Berkshire.

I was able to work in different GP practices with different staff and patient demographics, massively increasing my clinical experience, resilience and communication skills.

It also helped me funnelling down all the job offers I received through my locum work until I recently agreed for a salaried position in a GP practice that I love working at. "

Dr Nazar Ahmed

See the full list of features within our NASGP membership plans

Membership